Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 12/20 | 0.81 |
| ▸ | SYK | P43405 | 3/20 | 0.68 |
| ▸ | JAK3 | P52333 | 4/20 | 0.63 |
| ▸ | JAK2 | O60674 | 3/20 | 0.63 |
| ▸ | JAK1 | P23458 | 3/20 | 0.63 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.63 |
| ▸ | TYK2 | P29597 | 1/20 | 0.61 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14658244 | 0.91 | SYK (0.76) | STAT6SYKJAK3JAK2JAK1 | |
| SCHEMBL914729 | 0.89 | STAT6 (0.67) | STAT6SYKJAK3JAK2JAK1 | |
| SCHEMBL2387877 | 0.89 | STAT6 (0.73) | STAT6SYKJAK3JAK2JAK1 | |
| SCHEMBL913623 | 0.87 | STAT6 (0.64) | STAT6SYKJAK3JAK2JAK1 | |
| SCHEMBL763243 | 0.86 | STAT6 (0.69) | STAT6SYKJAK3JAK2JAK1 | |
| SCHEMBL20844385 | 0.86 | JAK3 (0.78) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL14862487 | 0.86 | STAT6 (0.68) | STAT6SYKJAK3JAK2JAK1 | |
| SCHEMBL913915 | 0.85 | JAK3 (0.63) | STAT6SYKJAK3JAK2JAK1 | |
| SCHEMBL14862458 | 0.85 | STAT6 (0.68) | STAT6SYKJAK3JAK2JAK1 | |
| SCHEMBL913709 | 0.85 | STAT6 (0.62) | STAT6SYKJAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| EP-1518855-B1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-8012959-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | STAT6 1/4885SYK 86/4885JAK3 10/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | STAT6 2/4885SYK 49/4885JAK3 11/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | STAT6 1/4885SYK 86/4885JAK3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.